ATE174629T1 - Herstellung von proteinen mittels protein 7b2 - Google Patents

Herstellung von proteinen mittels protein 7b2

Info

Publication number
ATE174629T1
ATE174629T1 AT92923809T AT92923809T ATE174629T1 AT E174629 T1 ATE174629 T1 AT E174629T1 AT 92923809 T AT92923809 T AT 92923809T AT 92923809 T AT92923809 T AT 92923809T AT E174629 T1 ATE174629 T1 AT E174629T1
Authority
AT
Austria
Prior art keywords
protein
pct
expressing
vivo
sec
Prior art date
Application number
AT92923809T
Other languages
English (en)
Inventor
Gerardus Julianus Mari Martens
Bhabatosh Chaudhuri
Christine Stephan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE174629T1 publication Critical patent/ATE174629T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722G-proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92923809T 1991-11-29 1992-11-27 Herstellung von proteinen mittels protein 7b2 ATE174629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9102009A NL9102009A (nl) 1991-11-29 1991-11-29 Produktie van bioactieve peptiden met recombinante cellen.

Publications (1)

Publication Number Publication Date
ATE174629T1 true ATE174629T1 (de) 1999-01-15

Family

ID=19859984

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92923809T ATE174629T1 (de) 1991-11-29 1992-11-27 Herstellung von proteinen mittels protein 7b2

Country Status (11)

Country Link
US (2) US5708140A (de)
EP (1) EP0614490B1 (de)
JP (1) JPH07501448A (de)
AT (1) ATE174629T1 (de)
AU (1) AU675919B2 (de)
CA (1) CA2123567A1 (de)
DE (1) DE69227921D1 (de)
FI (1) FI942442A (de)
HU (1) HUT67739A (de)
NL (1) NL9102009A (de)
WO (1) WO1993011248A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025681A1 (en) * 1992-06-11 1993-12-23 New York University A cytoplasmic chaperonin and methods of making and using it
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
WO1994008012A1 (en) * 1992-10-02 1994-04-14 Research Corporation Technologies, Inc. Methods for increasing secretion of overexpressed proteins
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
JPH09173078A (ja) * 1995-09-14 1997-07-08 Tadayuki Imanaka 分子シャペロンを用いる蛋白質の製造方法
JP2000512487A (ja) * 1996-05-14 2000-09-26 スミスクライン・ビーチャム・コーポレイション 新規化合物
US7569660B1 (en) 1999-06-09 2009-08-04 The University Of Chicago Recombinant prion-like proteins and materials comprising same
AU2001261242B2 (en) * 2000-05-03 2006-12-14 Expressive Constructs, Inc. A method for improving recombinant protein stability and solubility
JP4528460B2 (ja) * 2000-06-30 2010-08-18 株式会社東芝 半導体素子
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
WO2005004894A2 (en) * 2003-05-12 2005-01-20 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
FR3008713B1 (fr) * 2013-07-18 2016-11-25 Commissariat Energie Atomique Procede d'extraction et de purification d'acides nucleiques et tampons mis en œuvre

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8702590A (nl) * 1987-10-30 1989-05-16 Stichting Katholieke Univ Eiwit 7b2 alsmede recombinant dna en cdna, mrna, en antilichamen voor 7b2 en werkwijze voor het detecteren van 7b2.
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells

Also Published As

Publication number Publication date
NL9102009A (nl) 1993-06-16
DE69227921D1 (de) 1999-01-28
US5804417A (en) 1998-09-08
CA2123567A1 (en) 1993-06-10
EP0614490A1 (de) 1994-09-14
FI942442A (fi) 1994-07-25
EP0614490B1 (de) 1998-12-16
JPH07501448A (ja) 1995-02-16
AU675919B2 (en) 1997-02-27
US5708140A (en) 1998-01-13
HUT67739A (en) 1995-04-28
HU9401604D0 (en) 1994-09-28
FI942442A0 (fi) 1994-05-25
WO1993011248A1 (en) 1993-06-10
AU2946192A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
DE69227921D1 (de) Herstellung von Proteinen mittels Protein 7B2
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
DE69323879D1 (de) Herstellung von rekombinanten, menschlichem lactoferrin
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE68929551D1 (de) Menschliche DNase
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
NL189092C (nl) Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat.
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
DE69331045T2 (de) Verwendung von igf-1
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
ATE315091T1 (de) Modifizierte zellen auf der basis des betain- katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen
AU3347293A (en) Expression signal-peptide-free staphylokinases
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69132682T2 (de) Zellwachstumsinhibitoren
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
SE9300509D0 (sv) Peg treatment
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties